BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 18616803)

  • 1. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.
    Herszényi L; Farinati F; Cardin R; István G; Molnár LD; Hritz I; De Paoli M; Plebani M; Tulassay Z
    BMC Cancer; 2008 Jul; 8():194. PubMed ID: 18616803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of cysteine and serine proteases in colorectal carcinoma.
    Herszènyi L; Plebani M; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
    Cancer; 1999 Oct; 86(7):1135-42. PubMed ID: 10506696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cysteine and serine proteases in gastric cancer.
    Plebani M; Herszènyi L; Cardin R; Roveroni G; Carraro P; Paoli MD; Rugge M; Grigioni WF; Nitti D; Naccarato R
    Cancer; 1995 Aug; 76(3):367-75. PubMed ID: 8625115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis.
    Farinati F; Herszényi L; Plebani M; Carraro P; De Paoli M; Cardin R; Roveroni G; Rugge M; Nitti D; Grigioni WF; D'Errico A; Naccarato R
    Carcinogenesis; 1996 Dec; 17(12):2581-7. PubMed ID: 9006092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer].
    Herszényi L; Farinati F; Plebani M; István G; Sápi Z; Carraro P; De Paoli M; Naccarato R; Tulassay Z
    Orv Hetil; 1999 Aug; 140(33):1833-6. PubMed ID: 10489782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients.
    Levicar N; Kos J; Blejec A; Golouh R; Vrhovec I; Frkovic-Grazio S; Lah TT
    Cancer Detect Prev; 2002; 26(1):42-9. PubMed ID: 12088202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers.
    Herszényi L; István G; Cardin R; De Paoli M; Plebani M; Tulassay Z; Farinati F
    Eur J Cancer Prev; 2008 Oct; 17(5):438-45. PubMed ID: 18714186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI-1 and serum CEA.
    Høgdall CK; Christensen IJ; Stephens RW; Sørensen S; Nørgaard-Pedersen B; Nielsen HJ
    APMIS; 2002 Sep; 110(9):630-8. PubMed ID: 12529016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
    Harbeck N; Alt U; Berger U; Krüger A; Thomssen C; Jänicke F; Höfler H; Kates RE; Schmitt M
    Clin Cancer Res; 2001 Sep; 7(9):2757-64. PubMed ID: 11555589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators.
    Lah TT; Cercek M; Blejec A; Kos J; Gorodetsky E; Somers R; Daskal I
    Clin Cancer Res; 2000 Feb; 6(2):578-84. PubMed ID: 10690542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
    Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
    Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.
    Thomssen C; Oppelt P; Jänicke F; Ulm K; Harbeck N; Höfler H; Kuhn W; Graeff H; Schmitt M
    Anticancer Res; 1998; 18(3C):2173-80. PubMed ID: 9703780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of cathepsins B and L in primary human breast cancer.
    Foekens JA; Kos J; Peters HA; Krasovec M; Look MP; Cimerman N; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    J Clin Oncol; 1998 Mar; 16(3):1013-21. PubMed ID: 9508185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
    Harbeck N; Alt U; Berger U; Kates R; Krüger A; Thomssen C; Jänicke F; Graeff H; Schmitt M
    Int J Biol Markers; 2000; 15(1):79-83. PubMed ID: 10763146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer.
    Schweiger A; Christensen IJ; Nielsen HJ; Sørensen S; Brünner N; Kos J
    Int J Biol Markers; 2004; 19(4):289-94. PubMed ID: 15646835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.
    Huber K; Kirchheimer JC; Sedlmayer A; Bell C; Ermler D; Binder BR
    Cancer Res; 1993 Apr; 53(8):1788-93. PubMed ID: 8467497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
    Fujii T; Obara T; Tanno S; Ura H; Kohgo Y
    Hepatogastroenterology; 1999; 46(28):2299-308. PubMed ID: 10521987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas.
    Papadopoulou S; Scorilas A; Yotis J; Arnogianaki N; Plataniotis G; Agnanti N; Talieri M
    Tumour Biol; 2002; 23(3):170-8. PubMed ID: 12218297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.